Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-341	-283	-307	-267	53	-123
Depreciation & Amortization	10	10	8	6	4	3
Asset Writedown & Restructuring Costs	-	20	-	-	-	-
Loss (Gain) From Sale of Investments	-16	-25	-19	-	5	-
Stock-Based Compensation	62	76	73	65	55	22
Other Operating Activities	10	10	10	11	3	1
Change in Accounts Receivable	5	28	15	704	-17	-1
Change in Accounts Payable	29	3	-1	8	-5	9
Change in Unearned Revenue	-256	-56	-68	-112	-368	188
Change in Other Net Operating Assets	35	47	-17	23	14	12
Operating Cash Flow	-462	-170	-306	438	-256	111
Capital Expenditures	-2	-6	-24	-6	-26	-3
Investment in Securities	301	-78	218	-404	22	-431
Other Investing Activities	-	-	-	-3	-	-
Investing Cash Flow	299	-84	194	-413	-4	-434
Long-Term Debt Issued	-	47	-	-	-	-
Net Debt Issued (Repaid)	49	47	-	-	-	-
Issuance of Common Stock	156	237	33	23	232	439
Repurchase of Common Stock	-5	-7	-	-	-	-
Other Financing Activities	-	-	-	10	5	-
Financing Cash Flow	200	277	33	33	237	439
Net Cash Flow	37	23	-79	58	-23	116
Free Cash Flow	-464	-176	-330	432	-282	108
Free Cash Flow Margin	-193.33%	-68.22%	-282.05%	385.71%	-73.63%	138.46%
Free Cash Flow Per Share	-4.61	-1.95	-4.46	6.00	-3.81	1.97
Cash Interest Paid	1	1	-	-	-	-
Cash Income Tax Paid	-	-	5	3	-	-
Levered Free Cash Flow	-139.38	-41.25	-187.75	617.75	-644.75	40.73
Unlevered Free Cash Flow	-134.38	-38.75	-186.5	619	-644.75	40.73
Change in Working Capital	-187	22	-71	623	-376	208

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q